Shares of Cascadian Therapeutics Inc (NASDAQ:CASC) have received an average rating of “Hold” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $6.00.

Separately, Zacks Investment Research lowered shares of Cascadian Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th.

Several institutional investors and hedge funds have recently made changes to their positions in CASC. Schwab Charles Investment Management Inc. purchased a new stake in shares of Cascadian Therapeutics in the second quarter valued at about $225,000. Rhumbline Advisers purchased a new stake in shares of Cascadian Therapeutics in the second quarter valued at about $143,000. Bank of New York Mellon Corp grew its holdings in shares of Cascadian Therapeutics by 649.9% in the second quarter. Bank of New York Mellon Corp now owns 154,575 shares of the biopharmaceutical company’s stock valued at $574,000 after purchasing an additional 133,962 shares during the period. Teachers Advisors LLC purchased a new stake in shares of Cascadian Therapeutics in the second quarter valued at about $252,000. Finally, TIAA CREF Investment Management LLC purchased a new stake in shares of Cascadian Therapeutics in the second quarter valued at about $347,000. 80.33% of the stock is owned by hedge funds and other institutional investors.

Shares of Cascadian Therapeutics (CASC) opened at $4.07 on Tuesday. Cascadian Therapeutics has a 1-year low of $3.18 and a 1-year high of $4.97. The stock has a market cap of $205.78, a price-to-earnings ratio of -3.04 and a beta of 2.29.

Cascadian Therapeutics (NASDAQ:CASC) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.01. During the same quarter in the previous year, the business posted ($0.09) EPS. analysts predict that Cascadian Therapeutics will post -1.27 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Cascadian Therapeutics Inc (CASC) Receives Average Rating of “Hold” from Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/16/cascadian-therapeutics-inc-casc-receives-average-rating-of-hold-from-analysts.html.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Analyst Recommendations for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.